Tony Ho

Company: CRISPR Therapeutics
Job title: EVP, Head of Research & Development
Seminars:
Realizing the Clinical Potential of CRISPR/Cas9 for Best-in-Class Allogeneic Therapies 10:05 am
• Showcase clinical data from CTX110, CTX120 and CTX130 to review how allogeneic cells function in vivo • Analayze depth of response, persistence and durability of the allogeneic cells to achieve complete responses • How do allogeneic cells perform compared to autologous cell therapies?Read more
day: Day Two